Cue Biopharma Prices $50M Private Placement Near Market and Grants CEO 655K RSUs
CUE has more than doubled off its 52-week low of $4.971.
Summary
Cue Biopharma announced a $50M private placement from institutional investors and granted 1.06M RSUs to employees, including 655K to its CEO. The raise provides essential funding for clinical programs amid ongoing going-concern risks.
Key Events · Financing and Capital Events · CUE
-
$50M Private Placement
Institutional investors led by Cormorant Asset Management and Columbia Threadneedle purchased 1,418,071 shares at $33.21 and 87,500 pre-funded warrants at $33.209, generating approximately $50M in gross proceeds.
-
Dilution Impact
The 1.5M shares (including warrant shares) represent approximately 3.6% of the post-transaction outstanding shares, priced at a modest discount to the current $36.77 market price.
-
CEO RSU Grant
As part of a broader 1,064,492 RSU grant to employees and executives, CEO Shao-Lee Lin received 655,074 RSUs with time and performance-based vesting.
-
Use of Proceeds
Net proceeds will fund clinical development and general corporate purposes, addressing the company's going-concern warning and extending cash runway.
Analysis · CUE · Life Sciences
Cue Biopharma secured $50 million in a private placement priced at $33.21 per share — a modest discount to the current $36.77 price — from high-quality biotech investors including Cormorant Asset Management and Columbia Threadneedle. The raise extends the company's cash runway and funds clinical development, but it comes with dilution: the 1.5 million shares (including pre-funded warrants) represent roughly 3.6% of the post-transaction share count. Simultaneously, the board granted 1.06 million RSUs, with CEO Shao-Lee Lin receiving 655,074 units — a significant equity award that aligns leadership with shareholders but adds future dilution. The company remains under a going-concern warning, making this capital infusion critical for near-term survival.
How filings like this one have moved
In the 30 days to Aug 24, 2026, 37.5% of the 3362 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CUE was trading at $36.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $154.5M. The 52-week trading range was $4.97 to $45.50. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.